$ZBH

Zimmer Biomet (ZBH) extended its exclusive distribution agreement with Think Surgical for Think's TMINI robotic system, which complements ZBH's Rosa surgical robot portfolio and works with ZBH's Persona Knee System. Both companies cited the success of their partnership as the reason for the extension.

Zimmer Biomet extended its exclusive distribution agreement with Think Surgical for the TMINI robotic system. The deal covers multiple years and allows Zimmer to distribute a TMINI version compatible with its Persona knee system. Think Surgical aims to boost sales of the device, having recently raised $65 million and appointed a new VP of sales. According to Zimmer, the TMINI system complements its existing Rosa robotic knee system and contributes to its capital sales growth.

Solventum (NYSE:SOLV) reported Q2 revenue of $2.21B, up 2.2% YoY, beating estimates. STERIS (NYSE:STE) reported $1.49B, up 7.3% YoY, in line with expectations. BD (NYSE:BDX) reported $4.98B, up 5.4% YoY, beating estimates. CONMED (NYSE:CNMD) reported $343.5M, flat YoY, beating estimates. Stocks reacted accordingly.

RBC Capital's Kendall Au reaffirmed a Buy rating on Zimmer Biomet (ZBH) with a $110 price target. Shares closed at $88.06. The company reported Q2 revenue of $2.18B and net profit of $198.3M, up from $2.08B and $152.8M last year. Analyst consensus is Moderate Buy with a $106.07 target.

BMO Capital reiterated a Market Perform rating and $96 price target for Zimmer Biomet (ZBH) due to its iodine-coated hip implant opportunity in Japan, estimating a $72M steady-state opportunity. ZBH shares trade at $91.05, below the target. The company reported strong Q2 2026 earnings, exceeding expectations, with adjusted EPS of $2.07 and revenue of $2.18B. The firm's U.S. salesforce overhaul is progressing well, contributing to its positive outlook.

Thornal Kevin R (Grp Pres-Global Business) sold 5,691 shares of ZIMMER BIOMET HOLDINGS, INC. (ZBH) at $92.95 ($0.53M total) on 2026-09-11.

Phipps Chad F (See remarks below.) sold 3,000 shares of ZIMMER BIOMET HOLDINGS, INC. (ZBH) at $98.35 ($0.30M total) on 2026-09-04.

ZIMMER BIOMET HOLDINGS, INC. (ZBH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation Gary Campbell promoted to President, Americas Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery Bradley Kessler promoted to President, Americas

Zimmer Biomet Holdings (ZBH) announced a third-quarter 2026 cash dividend of $0.24 per share. The company's stock is trading at $100.04, with recent gains of 19.45% over 90 days and 6.50% over 30 days, but longer-term returns are down 4.72% over one year and 26.62% over five years. Analysts suggest the stock is 7% undervalued, with a fair value estimate of $107.57, citing growth in digital health and robotics. However, the company faces pricing pressures and integration challenges from recent ac

Zimmer Biomet (ZBH) reported Q2 results on Aug. 5, with adjusted EPS of $2.07 vs $2.01 expected and revenue of $2.2B vs $2.1B forecast. The company guided full-year adjusted EPS to $8.47-$8.59. Analysts covering ZBH have a Hold consensus, with a mean price target of $104.67 and a Street-high of $125.